Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer’s disease
and related human tauopathies. There is a growing body of evidence indicating that …

Neurodegeneration, induced by misfolded tau protein, and neuroinflammation, driven by
glial cells, represent the salient features of Alzheimer's disease (AD) and related human …

Protein kinases (PKs) have emerged as one of the most intensively investigated drug
targets in current pharmacological research, with indications ranging from oncology to …

Background Neurofibrillary pathology composed of tau protein is a main correlate of cognitive
impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau …

Truncated tau protein is the characteristic feature of human sporadic Alzheimer’s disease.
We have identified truncated tau proteins conformationally different from normal healthy tau. …

Carbonic anhydrase IX (CA IX) is a cancer-associated transmembrane isoform of zinc
metalloenzymes that catalyse interconversion between carbon dioxide and bicarbonate. CA IX is …

Introduction We have identified structural determinants on tau protein that are essential for
pathological tau–tau interaction in Alzheimer’s disease (AD). These regulatory domains, …

Alzheimer’s disease (AD) pathology is partly characterized by accumulation of aberrant forms
of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel…

Cognitive dysfunction syndrome (CDS) represents a group of symptoms related to the aging
of the canine brain. These changes ultimately lead to a decline of memory function and …

Human brain encompasses six tau isoforms, containing either three (3R) or four (4R) repeat
domains, all of which participate in the pathogenesis of human tauopathies. To investigate …